Volume 14 - Issue 2 - February, 2002

Prophylactic Abciximab in Elective Coronary Stenting: Results of a Randomized Trial

Corrado Tamburino, MD, Giovanni Russo, MD, Antonino Nicosia, MD,
Alfredo R. Galassi, MD, Rosario Foti, MD, V. Scriffignano, DSc, *Dean J. Kereiakes, MD, Giuseppe Giuffrida, MD

Recent large randomized trials have shown that abciximab [a potent inhibitor of platelet aggregation via glycoprotein (GP) IIb/IIIa blockade] is a safe and effective drug in reducing the incidence of death, myocardial infarction and the need for urgent revascularization after percutaneous transluminal coronary balloon angioplasty or coronary stent deployment.1,2 Furthermore, the use of abciximab in “high-risk” coronary angioplasty was associated with a significant reduction in target lesion revascularization at 6-month3 and 3-year follow-up.4
Intracoronary stents have been demonstrated to...

Role of the “Dogbone” Effect of Balloon-Expandable Stents: Quantitative Coronary Analysis of DUET and NIR Stent Implantation Int

Christoph Hehrlein, MD, *Jennifer J. DeVries, Amina Arab, MD, *Scott D. Haller, MS,
*Ann Kloostra, RN, *Michael A. Lauer, MD, *Malcom T. Foster, MD, *Tim A. Fischell, MD

Stent implantation has made its way into widespread clinical use since improvements in stent design and stent delivery systems facilitated deployment even in coronary lesions that are difficult to access. A variety of different stent designs are now available, which may, along with their delivery systems, account for different acute performance characteristics and clinical outcomes. Rieu et al. recently showed that the radial force of stenting determining elastic recoil of the coronary arteries varies considerably among different types of stent.1
The Multi-Link DUET stent (Guidant Corporation...

The Interventional Approach to the Acute Coronary Syndromes

Lloyd W. Klein, MD, FACC

In this month's issue of the Journal of Invasive Cardiology, a new section dedicated to the invasive and interventional management of acute coronary syndromes (ACS) is being launched. This is an exciting opportunity for our community to share the latest observations in pathogenesis, treatment strategies and leading edge pharmacologic adjuncts useful in the therapy of patients with acute chest pain.
It is a dream role for me to serve as Section Editor because of my dual interests in interventional cardiology and management of acute ischemia. My goal is to develop a different kind of education...

Editorial Staff
  • Executive Officer
    Laurie Gustafson
  • Production
    Elizabeth Vasil
  • National Account Manager
    Jeff Benson
  • Senior Account Director
    Carson McGarrity
  • Special Projects Editor
    Amanda Wright
Editorial Correspondence

Back to top